Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid ...

Learn more about whether Neurocrine Biosciences, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Ionis Pharmaceuticals, Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's ...

Asthma Drugs Market Oral and injectable forms are expanding, especially for patients with severe asthma and those undergoing biologic treat ...

The company, also known as DRW, shared early data on its forthcoming multiplex qPCR-based platform and infectious disease ...

Samsung unveils the Galaxy Tab Active 5 Pro, a rugged Android tablet with hot-swappable batteries, durable design, and ...

Kerry footballer Darragh Roche made an emotional return to Gaelic football a fortnight ago having suffered a heart attack ...

Roche has parted with $1.4 billion upfront to ... another $250 million over the next two years and could be worth up to $5.3 billion to Denmark-based Zealand if clinical and sales milestones ...

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary endpoint of superior A1C reduction vs. placebo at 40 weeks.

Roche will present the new data at next week's ASCO congress showing that its bispecific antibody glofitamab can achieve high and durable responses in patients with aggressive lymphoma. The ...

As per Vantage Market Research, the Pharmaceutical Manufacturing Market is poised for growth due to various factors, such as ...

Biotechnology Reagents Market As per MRFR analysis, the Biotechnology Reagents Market Growth Size was estimated at 44.6 (USD Billion) in 20 ...